FIELD: biotechnology.
SUBSTANCE: invention relates to crystals of 1-((2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluor-2-methylpropane-2-ol characterized by the formula (1). A crystal of type I of 1-((2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluor-2-methylpropane-2-ol has, on X-ray powder diffraction pattern, characteristic peaks with diffraction angles (2θ±0.2°) equal to 7.7°, 14.5°, 17.0°, 18.9°, 19.4°, 23.3°, and 25.7°. A crystal of type II of 1-((2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluor-2-methylpropane-2-ol has, on X-ray powder diffraction pattern, characteristic peaks with diffraction angles (2θ±0.2°) equal to 7.8°, 14.7°, 15.7°, 19.3°, and 25.0°. The invention also relates to a pharmaceutical composition having an inhibitory effect on phosphodiesterase (PDE) 4, including a crystal of 1-((2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluor-2-methylpropane-2-ol characterized by the formula (1) as an active principle.
EFFECT: crystal forms of 1-((2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluor-2-methylpropane-2-ol, having a stability property.
6 cl, 3 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUND AND ITS PHARMACOLOGICALLY ACCEPTABLE SALT | 2017 |
|
RU2767878C2 |
| NEW CRYSTAL FORM OF VASCULAR PERMEABILITY BLOCKER COMPOUND | 2020 |
|
RU2809162C2 |
| PYRIMIDINE COMPOUND CRYSTAL | 2021 |
|
RU2828232C1 |
| CRYSTALS OF 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND | 2016 |
|
RU2672563C1 |
| NEW 4-{3-[4-(3-{4-[AMINO(BUTOXYCARBONYLIMINO)METHYL]PHENOXY}PROPYL)-1-PIPERIDINYL]PROPOXY}-N'-(BUTOXYCARBONYL)BENZAMIDINE CRYSTALS | 2008 |
|
RU2456272C2 |
| SALT AND CRYSTALLINE FORM OF COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | 2020 |
|
RU2833357C2 |
| METHOD OF PRODUCING A THIAZOLE DERIVATIVE | 2016 |
|
RU2738937C2 |
| CRYSTAL SUBSTANCE OF HETEROCYCLIDENACETAMIDE DERIVATIVE | 2018 |
|
RU2779198C2 |
| CRYSTAL FORM AND SALT 3-(3,5-DICHLORO-4-HYDROXYBENZOIL)- 1,1-DIOXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE | 2018 |
|
RU2772043C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND POSSESSING ACTIVITY OF THROMBOPOIETIN RECEPTOR AGONIST, AND INTERMEDIATE COMPOUND THEREFOR | 2008 |
|
RU2476429C2 |
